ELVN Stock Forecast: Enliven Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$47
+0.26% on the day

The 14 Wall Street analysts covering Enliven Therapeutics, Inc. hold a median 12-month price target of $74 — +59.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 77 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$3.4B
Ticker Nerd rank
77/ 100
Median analyst target
$74
Analysts covering
14
Revenue$0.0
Operating income−$37.2M
Net income−$32.5M
Free cash flow−$18.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.7%
1M
+12.8%
YTD
+202.1%
1Y
+118.8%
From 52W high
−23.9%
From 52W low
+207.3%
$15
$61
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Enliven Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
77/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
96
Value
90
Volatility
86
Quality
80
Revisions
69
Accruals
55
Growth
34
Issuance
27

Momentum (96): The shares have been drifting up relative to others.

Issuance (27): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ELVN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ELVN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80Jan 26Apr 26Jul 26Oct 26ELVNHigh $82Median $74Low $69

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
14
Buy
0
Hold
0
Sell
$69
Low
$74
Median
$82
High

The green dot is the last close — the median target sits +59.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
6 Nov 2026GuggenheimReiteratesBuy$78
19 Oct 2026HC Wainwright & Co.MaintainsBuy$65 → $73
2 Oct 2026Morgan StanleyInitiatesOverweight$70
1 Oct 2026JP MorganInitiatesOverweight$75
18 Aug 2026BarclaysInitiatesOverweight$78
18 Aug 2026MizuhoMaintainsOutperform$62 → $73
18 Aug 2026William BlairInitiatesOutperform—
6 Aug 2026Goldman SachsMaintainsBuy$67 → $80
6 Aug 2026GuggenheimMaintainsBuy$80 → $78
6 Aug 2026StifelMaintainsBuy$80 → $82
21 July 2026Goldman SachsMaintainsBuy$59 → $67
9 July 2026HC Wainwright & Co.MaintainsBuy$56 → $64
1 July 2026StifelMaintainsBuy—
29 June 2026Jones TradingMaintainsBuy—
9 June 2026StifelInitiatesBuy—
2 June 2026MizuhoMaintainsOutperform—
8 May 2026Goldman SachsMaintainsBuy—
26 Mar 2026HC Wainwright & Co.MaintainsBuy—
25 Mar 2026MizuhoMaintainsOutperform—
2 July 2025HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ELVN.

Market Radar

This page is one stock. Monday covers all of them.

ELVN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ELVN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Enliven Therapeutics, Inc. returned +118.8% against +6.9% for the S&P 500, dividends included.

ELVN vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250300Jan 26Apr 26Jul 26Oct 26ELVNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ELVN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
4
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
3.9×

Cheaper than 24% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−16.8%

Higher than 33% of US stocks

Return on assets
−12.2%

Higher than 25% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Enliven Therapeutics, Inc. has a market value of $3.4B and an enterprise value of $2.5B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$105.9M.

  • Diluted earnings per share, trailing twelve months: −$1.67.

  • Free cash flow in the twelve months to 30 June 2026: −$67.0M.

  • Shares outstanding: 73.3M.

  • Enliven Therapeutics, Inc. employs 65 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

ELVN and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ELVNEnliven Therapeutics, Inc.$3.4B77
IRONDisc Medicine, Inc.$3.3B42
VRDNViridian Therapeutics, Inc.$3.3B60
ARQTArcutis Biotherapeutics, Inc.$3.3B69
PBLSParabilis Medicines, Inc.$3.4B2
RLAYRelay Therapeutics, Inc.$3.5B80
ABCLAbCellera Biologics, Inc.$3.1B78

Take a look at ELVN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Enliven Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ELVN

What is the ELVN stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Enliven Therapeutics, Inc. have a median 12-month price target of $74, with estimates ranging from $69 to $82. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ELVN stock a buy right now?

Of the 14 analysts covering Enliven Therapeutics, Inc., 14 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Enliven Therapeutics, Inc. 77 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ELVN?

As at 21 Nov 2026, Enliven Therapeutics, Inc. ranks 77 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).

Will ELVN stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +59.0% from the last close, and Ticker Nerd's factor model ranks Enliven Therapeutics, Inc. 77 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ELVN stock forecast for 2030?

No analyst covering Enliven Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $69 to $82 over the next 12 months.

How has ELVN stock performed over the past year?

Enliven Therapeutics, Inc. returned +118.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Enliven Therapeutics, Inc. do?

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for cancer. The company’s current pipeline centers on precision oncology programs designed to target clinically validated pathways with greater selectivity and improved tolerability.

Company

About Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for cancer. The company’s current pipeline centers on precision oncology programs designed to target clinically validated pathways with greater selectivity and improved tolerability. Its lead candidates include ELVN-001, a kinase inhibitor being evaluated for chronic myeloid leukemia, and ELVN-002, a CNS-penetrant HER2 inhibitor being studied in HER2-altered solid tumors such as non-small cell lung cancer. Enliven Therapeutics, Inc. operates in the oncology drug development market, where small molecule inhibitors play an important role in addressing unmet needs across liquid and solid tumors. The company is headquartered in Boulder, Colorado, and is organized around research and early-stage clinical development of targeted cancer therapies.

CEO Mr. Richard A. Fair M.B.A. · 65 employees · United States · https://www.enliventherapeutics.com